These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37080708)

  • 1. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
    Eckrich MJ; Frangoul H
    Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34
    Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ
    Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for sickle cell disease: An update.
    Demirci S; Uchida N; Tisdale JF
    Cytotherapy; 2018 Jul; 20(7):899-910. PubMed ID: 29859773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 gene editing for curing sickle cell disease.
    Park SH; Bao G
    Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.
    Handgretinger R; Mezger M
    Expert Opin Biol Ther; 2024 Sep; 24(9):883-888. PubMed ID: 39222044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
    Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
    Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
    Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
    Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
    Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
    Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
    Lohani N; Bhargava N; Munshi A; Ramalingam S
    J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice.
    Wilkinson AC; Dever DP; Baik R; Camarena J; Hsu I; Charlesworth CT; Morita C; Nakauchi H; Porteus MH
    Nat Commun; 2021 Jan; 12(1):686. PubMed ID: 33514718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
    Mahmoud Ahmed NH; Lai MI
    Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
    Parums DV
    Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
    Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
    Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.